CARsgen Therapeutics announces 2026 interim results

CARsgen Therapeutics Holdings Limited has announced its 2026 interim results, highlighting the approval of satri-cel by the NMPA in June 2026. Satri-cel is noted as the world’s first and only CAR-T therapy for solid tumors.

As of June 30, 2026, the company reported cash and cash equivalents of approximately RMB1,400 million. It expects to maintain cash levels of at least RMB1,200 million by the end of 2026, with sufficient liquidity projected through 2030. During the first half of 2026, the company received 110 confirmed orders for zevor-cel through its partner, Huadong Medicine.

The company is also advancing several products under its proprietary THANK-u Plus® and CARvivo™ platforms. Recent developments include IND approvals from the NMPA for CT0596 and CT1190B in August 2026, and the initiation of an investigator-initiated trial for KJ-C2529.